Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
International Penile Advanced Cancer Trial International Rare Cancers Initiative study
Study Type: Treatment
Phase: III
NCTID: NCT02305654
Principal Investigator:
Elizabeth Wulff-Burchfield
Phase III Randomized Trial of Standard Systemic Therapy SST versus Standard Systemic Therapy Plus Definitive Treatment Surgery or Radiation of the Primary Tumor in Metastatic Prostate Cancer
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Study Type: Treatment
Phase: III
NCTID: NCT02521493
Principal Investigator:
Keith August
PREcision DIagnostics in Prostate Cancer Treatment PREDICT
Study Type: Treatment
Phase: II
NCTID: NCT06632977
Principal Investigator:
Elizabeth Wulff-Burchfield
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
Study Type: Treatment
Phase: III
NCTID: NCT02900976
Principal Investigator:
Keith August
The Cancer Tracking System CATSystem: A Randomized control trial to evaluate a systems level intervention for cervical cancer screening, treatment, referral and follow up in Kenya.
Study Type: Health Services
Phase: N/A
NCTID: NCT06286462
Principal Investigator:
Sarah Kessler
A Randomized Trial Addressing Cancer-Related Financial Hardship through Delivery of a Proactive Financial Navigation Intervention CREDIT
SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ?50 or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression
Study Type: Treatment
Phase: III
NCTID: NCT06119581
Principal Investigator:
Jun Zhang
A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase ALK Fusion Protein
Changing the Default for Tobacco Treatment
Study Type: Prevention
Phase: IV
NCTID: NCT02721082
Principal Investigator:
Kimber Richter